A compound as a potassium channel regulator and preparation and use thereof are described. Specifically, the compound has the structure shown in formula A. A preparation method of the compound and its use as a potassium channel regulator in a medicament and a pharmaceutical composition are also described.

##STR00001##

A compound as a potassium channel regulator and preparation and use thereof are described. Specifically, the compound has the structure shown in formula A. A preparation method of the compound and its use as a potassium channel regulator in a medicament and a pharmaceutical composition are also described.

##STR00001##

Disclosed herein, inter alia, are inhibitors of alpha 2 beta 1 integrin and methods of using the same.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The present application relates methods for treating a depressive symptom comprising administering an effective amount of a μ opioid receptor agonist or a pharmaceutically acceptable salt thereof to a subject in need thereof. Non-limiting examples of such agonist include the compounds of Formulas I, II, III, and IV, as well as the compounds of Table A.

The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.

The present invention describes compounds and uses thereof in applications relating to absorption of electromagnetic energy. Preferred compounds are double bond-containing compounds capable of absorbing electromagnetic radiation energy and having improved properties.

A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT.sub.7 receptor (5-HT.sub.7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injection (i.p.) or by oral administration (p.o.). These 5-HT.sub.7 receptor antagonists are a new class of therapeutic agents for the treatment of IBS. ##STR00001##

A series of 8-phenyl-isoquinoline derivatives (I) exhibit high binding affinity to 5-HT.sub.7 receptor (5-HT.sub.7R) and demonstrate potent antinociceptive activity in two animal models for Irritable Bowel Syndrome (IBS) by intraperitoneal injection (i.p.) or by oral administration (p.o.). These 5-HT.sub.7 receptor antagonists are a new class of therapeutic agents for the treatment of IBS. ##STR00001##

Compositions and methods are provided for treating HPV infections including pre-malignant and cancers. Compounds that specifically bind to the HPV E6 protein and inactivate the protein are disclosed.